Opinion · 1 Dec 2025
Conference abstractPublished 3 Aug 2015
Pre-therapy initial dosimetry results of Lu-177-PSMA-DOTA-617 in castration resistant prostate cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aim: Targeted radionuclide therapy (TRT) is an increasingly used treatment modality for wide range of cancers. Presently dosimetry is highly required either to plan treatment or to ascertain the absorbed dose delivered to critical organs during treatment. Materials & Methods: The study comprised of 7 patients suffering from prostate cancer with progressive disease and candidated to undergo Lu-177-DOTA-617 therapy following Ga-68-PSMA PET/CT imaging for all patients. 192.4±11.1 Mbq (5.2±0.3 mCi) was intravenously injected and to evaluate bone marrow absorbed dose 2 cc blood samples were withdrawn in short variable times (3, 15, 30, 60, 180. Minutes and 24, 48, 120. hours) after injection. Furthermore whole body scans were performed using scintillation gama camera in 4, 24, 48 and 120 hour after injection and in order to quantify the activity takenup in the body, kidneys, liver, right parotid and left parotid, the geometric mean of anterior and posterior counts were determined through ROI analysis. After that, background subtraction and attenuation correction were applied using patients Ga-68-PSMA PET/CT images taken in a consideration; organ thickness, body thickness and Hounsfield unites from Computed Tomography scan. OLINDA/EXM dosimetry program was used for curvefitting, residence time calculation and absorbed dose calculations. Results: Calculated absorbed dose of bone marrow, left kidney, right kidney, liver, left parotid, right parotid and total body. 1.39±0.56, 32.36±16.36, 32.7±13.68,10.35±3.45, 38.67±21.29, 37.55±19.77, 2.25±0.95 (mGy/mCi) respectively. Conclusions: Our first results clarify that Lu-177-DOTA-617 is safe and reliable therapy as there were no complications seen. On the other hand, the observable variation in the absorbed dose of the critical organs among the patients necessitate patient- specific dosimetry approach to save body organs and particularly highly exposed kidneys and parotid gland.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Nuclear Medicine & Radiation Therapy.
Brief report · 1 Dec 2025
AI: Precision Radionuclide Therapy Dosimetry Advancements
Brief report · 1 Dec 2025
Multi-Isotope Therapy: Powering Precision Nuclear Oncology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalNuclear Medicine & Radiation Therapy
- SubjectRadiology & Imaging
- SubjectEnergy & Power
- BylineArticles whose byline prints “Abuqbeitah Mohammad”
- BylineArticles whose byline prints “Yeyin Nami”
- BylineArticles whose byline prints “Aygun Aslan”
- BylineArticles whose byline prints “Demirci Emre”
- BylineArticles whose byline prints “Ocak Meltem”
- BylineArticles whose byline prints “Kabasakal Levent”
